Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

Core Viewpoint - Optinose has announced the cancellation of its earnings conference call due to its acquisition by Paratek Pharmaceuticals, which is subject to shareholder approval and customary closing conditions [1][2]. Company Overview - Optinose is a specialty pharmaceutical company that focuses on patients treated by ear, nose, and throat (ENT) and allergy specialists [3]. - The company aims to report its financial results for the three- and twelve-month periods ended December 31, 2024, in a timely manner following the acquisition announcement [2]. Acquisition Details - Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, which will require shareholder approval and other customary closing conditions [2]. - The earnings conference call that was scheduled for March 20, 2025, has been cancelled as a result of this acquisition announcement [1][2].